Iron metabolism regulates p53 signaling through direct Heme-p53 interaction and modulation of p53 localization, stability, and function

Cell Reports

Volumn 7, Issue 1, 2014, Pages 180-193

  Shen, Jia ^a,b   Sheng, Xiangpeng ^a,b   Chang, ZeNan ^d,h   Wu, Qian ^b,c   Wang, Sheng ^a,b   Xuan, Zongliang ^f   Li, Dan ^a,b   Wu, Yalan ^a   Shang, Yongjia ^f   Kong, Xiangtao ^a   Yu, Long ^g   Li, Lin ^a   Ruan, Kangchen ^a   Hu, Hongyu ^a   Huang, Ying ^a   Hui, Lijian ^a   Xie, Dong ^c   Wang, Fudi ^e   Hu, Ronggui ^a  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^d CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^e ZHEJIANG UNIVERSITY   (China)

^f ANHUI NORMAL UNIVERSITY   (China)

^g FUDAN UNIVERSITY   (China)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; HEME; PROTEIN P53; HIF1A PROTEIN, HUMAN; HIF1A PROTEIN, MOUSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON; TP53 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CARBOXY TERMINAL SEQUENCE; CARCINOGENICITY; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IRON CHELATION; IRON METABOLISM; MALE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; ACTIVE TRANSPORT; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CARCINOGENESIS; CHEMICAL STRUCTURE; CYTOSOL; DOWN REGULATION; GENETIC TRANSCRIPTION; IRON OVERLOAD; KNOCKOUT MOUSE; METABOLISM; MOLECULAR GENETICS; SEQUENCE HOMOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL CULTURE; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; AMINO ACID SEQUENCE; ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; CYTOSOL; DOWN-REGULATION; HEME; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IRON; IRON OVERLOAD; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84898027188     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.02.042     Document Type: Article

References (64)

1. Abeysinghe R.D., Greene B.T., Haynes R., Willingham M.C., Turner J., Planalp R.P., Brechbiel M.W., Torti F.M., Torti S.V. p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Carcinogenesis 2001, 22:1607-1614.
2. An W.G., Kanekal M., Simon M.C., Maltepe E., Blagosklonny M.V., Neckers L.M. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 1998, 392:405-408.
3. Andrews N.C. Forging a field: the golden age of iron biology. Blood 2008, 112:219-230.
4. Ashcroft M., Taya Y., Vousden K.H. Stress signals utilize multiple pathways to stabilize p53. Mol. Cell. Biol. 2000, 20:3224-3233.
5. Ba Q., Hao M., Huang H., Hou J., Ge S., Zhang Z., Yin J., Chu R., Jiang H., Wang F., et al. Iron deprivation suppresses hepatocellularcarcinoma growth in experimental studies. Clin. Cancer Res. 2011, 17:7625-7633.
6. Baker S.J., Fearon E.R., Nigro J.M., Hamilton S.R., Preisinger A.C., Jessup J.M., vanTuinen P., Ledbetter D.H., Barker D.F., Nakamura Y., et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989, 244:217-221.
7. Boon E.M., Huang S.H., Marletta M.A. A molecular basis for NO selectivity in soluble guanylate cyclase. Nat. Chem. Biol. 2005, 1:53-59.
8. Brooks C.L., Gu W. p53 regulation by ubiquitin. FEBS Lett. 2011, 585:2803-2809.
9. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
10. Buss J.L., Greene B.T., Turner J., Torti F.M., Torti S.V. Ironchelators in cancer chemotherapy. Curr. Top. Med. Chem. 2004, 4:1623-1635.
11. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994, 265:346-355.
12. Dioum E.M., Rutter J., Tuckerman J.R., Gonzalez G., Gilles-Gonzalez M.A., McKnight S.L. NPAS2: a gas-responsive transcription factor. Science 2002, 298:2385-2387.
13. Elmberg M., Hultcrantz R., Ekbom A., Brandt L., Olsson S., Olsson R., Lindgren S., Lööf L., Stål P., Wallerstedt S., et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003, 125:1733-1741.
14. Espinosa J.M., Verdun R.E., Emerson B.M. p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol. Cell 2003, 12:1015-1027.
15. Faller M., Matsunaga M., Yin S., Loo J.A., Guo F. Heme is involved in microRNA processing. Nat. Struct. Mol. Biol. 2007, 14:23-29.
16. Fasano O., Birnbaum D., Edlund L., Fogh J., Wigler M. New human transforming genes detected by a tumorigenicity assay. Mol. Cell. Biol. 1984, 4:1695-1705.
17. Fleming R.E., Ponka P. Iron overload in human disease. N.Engl. J. Med. 2012, 366:348-359.
18. Frebourg T., Barbier N., Yan Y.X., Garber J.E., Dreyfus M., Fraumeni J., Li F.P., Friend S.H. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am. J. Hum. Genet. 1995, 56:608-615.
19. Friedman P.N., Chen X., Bargonetti J., Prives C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc. Natl. Acad. Sci. USA 1993, 90:3319-3323.
20. Gilles-Gonzalez M.A., Gonzalez G. Heme-based sensors: defining characteristics, recent developments, and regulatory hypotheses. J.Inorg. Biochem. 2005, 99:1-22.
21. Hainaut P., Milner J. Redox modulation of p53 conformation and sequence-specific DNA binding invitro. Cancer Res. 1993, 53:4469-4473.
22. Hu R.G., Sheng J., Qi X., Xu Z., Takahashi T.T., Varshavsky A. The N-end rule pathway as a nitric oxide sensor controlling the levels of multiple regulators. Nature 2005, 437:981-986.
23. Hu R.G., Wang H., Xia Z., Varshavsky A. The N-end rule pathway is a sensor of heme. Proc. Natl. Acad. Sci. USA 2008, 105:76-81.
24. Ishikawa H., Kato M., Hori H., Ishimori K., Kirisako T., Tokunaga F., Iwai K. Involvement of heme regulatory motif in heme-mediated ubiquitination and degradation of IRP2. Mol. Cell 2005, 19:171-181.
25. Jayaraman J., Prives C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 1995, 81:1021-1029.
26. Jiang P., Du W., Mancuso A., Wellen K.E., Yang X. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature 2013, 493:689-693.
27. Kaelin W.G. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin. Cancer Res. 2004, 10:6290S-6295S.
28. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991, 51:6304-6311.
29. Kwon Y.T., Kashina A.S., Davydov I.V., Hu R.G., An J.Y., Seo J.W., Du F., Varshavsky A. An essential role of N-terminal arginylation in cardiovascular development. Science 2002, 297:96-99.
30. Larkin M.A., Blackshields G., Brown N.P., Chenna R., McGettigan P.A., McWilliam H., Valentin F., Wallace I.M., Wilm A., Lopez R., et al. Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23:2947-2948.
31. Lee J., Lee Y., Lee M.J., Park E., Kang S.H., Chung C.H., Lee K.H., Kim K. Dual modification of BMAL1 by SUMO2/3 and ubiquitin promotes circadian activation of the CLOCK/BMAL1 complex. Mol. Cell. Biol. 2008, 28:6056-6065.
32. Liang S.X., Richardson D.R. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. Carcinogenesis 2003, 24:1601-1614.
33. Liu J., Xia H., Kim M., Xu L., Li Y., Zhang L., Cai Y., Norberg H.V., Zhang T., Furuya T., et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 2011, 147:223-234.
34. Maddocks O.D., Vousden K.H. Metabolic regulation by p53. J.Mol. Med. (Berl.) 2011, 89:237-245.
35. McLure K.G., Takagi M., Kastan M.B. NAD+ modulates p53 DNA binding specificity and function. Mol. Cell. Biol. 2004, 24:9958-9967.
36. Niederau C., Fischer R., Sonnenberg A., Stremmel W., Trampisch H.J., Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N.Engl. J. Med. 1985, 313:1256-1262.
37. Osborne N.J., Gurrin L.C., Allen K.J., Constantine C.C., Delatycki M.B., McLaren C.E., Gertig D.M., Anderson G.J., Southey M.C., Olynyk J.K., et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology 2010, 51:1311-1318.
38. Pack M., Trumpfheller C., Thomas D., Park C.G., Granelli-Piperno A., Münz C., Steinman R.M. DEC-205/CD205+ dendritic cells are abundant in the white pulp of the human spleen, including the border region between the red and white pulp. Immunology 2008, 123:438-446.
39. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 2010, 139:393-408.
40. Ponka P. Cell biology of heme. Am. J. Med. Sci. 1999, 318:241-256.
41. Radulescu S., Brookes M.J., Salgueiro P., Ridgway R.A., McGhee E., Anderson K., Ford S.J., Stones D.H., Iqbal T.H., Tselepis C., Sansom O.J. Luminal iron levels govern intestinal tumorigenesis after Apc loss invivo. Cell Rep. 2012, 2:270-282.
42. Rajagopal A., Rao A.U., Amigo J., Tian M., Upadhyay S.K., Hall C., Uhm S., Mathew M.K., Fleming M.D., Paw B.H., et al. Haem homeostasis is regulated by the conserved and concerted functions of HRG-1 proteins. Nature 2008, 453:1127-1131.
43. Reinking J., Lam M.M., Pardee K., Sampson H.M., Liu S., Yang P., Williams S., White W., Lajoie G., Edwards A., Krause H.M. The Drosophila nuclear receptor e75 contains heme and is gas responsive. Cell 2005, 122:195-207.
44. Rouault T.A. Linking physiological functions of iron. Nat. Chem. Biol. 2005, 1:193-194.
45. Simcox J.A., McClain D.A. Iron and diabetes risk. Cell Metab. 2013, 17:329-341.
46. Stommel J.M., Marchenko N.D., Jimenez G.S., Moll U.M., Hope T.J., Wahl G.M. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 1999, 18:1660-1672.
47. Tavana O., Gu W. The Hunger Games: p53 regulates metabolism upon serine starvation. Cell Metab. 2013, 17:159-161.
48. Torti S.V., Torti F.M. Iron and cancer: more ore to be mined. Nat. Rev. Cancer 2013, 13:342-355.
49. Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci. 2009, 100:9-16.
50. Turner J., Koumenis C., Kute T.E., Planalp R.P., Brechbiel M.W., Beardsley D., Cody B., Brown K.D., Torti F.M., Torti S.V. Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation. Blood 2005, 106:3191-3199.
51. Varshavsky A. The ubiquitin system, an immense realm. Annu. Rev. Biochem. 2012, 81:167-176.
52. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
53. Vousden K.H., Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431.
54. Wang Q., Jiang L., Wang J., Li S., Yu Y., You J., Zeng R., Gao X., Rui L., Li W., Liu Y. Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice. Hepatology 2009, 49:1166-1175.
55. Weiss G. Genetic mechanisms and modifying factors in hereditary hemochromatosis. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:50-58.
56. Whitnall M., Howard J., Ponka P., Richardson D.R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. USA 2006, 103:14901-14906.
57. Wu N., Yin L., Hanniman E.A., Joshi S., Lazar M.A. Negative feedback maintenance of heme homeostasis by its receptor, Rev-erbalpha. Genes Dev. 2009, 23:2201-2209.
58. Wu Z., Jiang Q., Clarke P.R., Zhang C. Phosphorylation of Crm1 by CDK1-cyclin-B promotes Ran-dependent mitotic spindle assembly. J.Cell Sci. 2013, 126:3417-3428.
59. Yamasaki T., Terai S., Sakaida I. Deferoxamine for advanced hepatocellular carcinoma. N.Engl. J. Med. 2011, 365:576-578.
60. Yang F., Xia X.A., Lei H.Y., Wang E.D. Hemin binds to human cytoplasmic arginyl-tRNA synthetase and inhibits its catalytic activity. J.Biol. Chem. 2010, 285:39437-39446.
61. Yin L., Wu N., Curtin J.C., Qatanani M., Szwergold N.R., Reid R.A., Waitt G.M., Parks D.J., Pearce K.H., Wisely G.B., Lazar M.A. Rev-erbalpha, a heme sensor that coordinates metabolic and circadian pathways. Science 2007, 318:1786-1789.
62. Zhang L., Guarente L. Heme binds to a short sequence that serves a regulatory function in diverse proteins. EMBO J. 1995, 14:313-320.
63. Zhao R., Planalp R.P., Ma R., Greene B.T., Jones B.T., Brechbiel M.W., Torti F.M., Torti S.V. Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Biochem. Pharmacol. 2004, 67:1677-1688.
64. Zhou X.Y., Tomatsu S., Fleming R.E., Parkkila S., Waheed A., Jiang J., Fei Y., Brunt E.M., Ruddy D.A., Prass C.E., et al. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc. Natl. Acad. Sci. USA 1998, 95:2492-2497.